

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Beijing Airdoc Technology Co., Ltd.**  
**北京鷹瞳科技發展股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2251)**

**PROFIT ALERT — REDUCTION IN LOSS**

This announcement is made by the board (the “**Board**”) of directors of Beijing Airdoc Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on its preliminary assessment of the unaudited consolidated management accounts for the Group for the six months ended June 30, 2023 and information currently available to the management of the Group, the Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors the following updates on the Group’s operating results:

1. the Group is expected to record a revenue ranging from RMB78 million to RMB84 million for the six months ended June 30, 2023, representing an increase in the range of 109% to 125% from RMB37.4 million for the six months ended June 30, 2022. The increase in the revenue of the Group is mainly attributable to (i) the further expansion of Group’s main business, including a continuous increase in coverage of hospitals and primary healthcare institutions; and (ii) the development in its integrated diagnostics business, including the business in relation to prevention and control of myopia and amblyopia; and

- the loss of the Group for the six months ended June 30, 2023 is expected to decrease by approximately 57.9% to 67.9% as compared to the corresponding period in 2022. The decrease in the loss of the Group is mainly attributable to (i) the continuous improvement in the Group's operational efficiency; (ii) the significant increase in the Group's revenue; and (iii) the improvement in the gross profit margin due to enhanced cost control.

The information contained in this announcement is unaudited and only based on a preliminary assessment by the Board with reference to the information currently available to the management, which has not been audited or reviewed by the independent auditors of the Company or confirmed by the audit committee of the Company, and thus may be subject to further adjustments and may differ from the figures to be disclosed in the interim results to be published by the Company.

As of the date of this announcement, the Company is still in the process of finalizing the unaudited consolidated results for the six months ended June 30, 2023, which is expected to be published before the end of August 2023 in accordance with the requirements of the Listing Rules.

**Shareholders and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company.**

By order of the Board  
**Beijing Airdoc Technology Co., Ltd.**  
**Mr. ZHANG Dalei**  
*Chairman of the Board*

Hong Kong, July 31, 2023

*As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Dr. CHEN Yuzhong, Mr. CHEN Hailong and Ms. WANG Lin as executive directors; Mr. CHEN Xin as a non-executive director; and Mr. NG Kong Ping Albert, Dr. WU Yangfeng and Dr. HUANG Yanlin as independent non-executive directors.*